Login
Companies $VIR
$9.62 +$0.04 (0.42%) After hours
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

vir.bio

What Do They Do?

Develops investigational medicines for serious infectious diseases and cancer, including treatments for hepatitis delta and solid tumors.

How Do They Make Money?

License and collaboration agreements are the main revenue source; partners may pay upfront, reimburse research, pay milestones, share profits, and pay royalties on sales. Research-service amounts can come in as Vir performs the work, while royalties depend on partner sales.

revenue
SegmentShareRevenue
License and collaboration revenue
92%
Grant revenue
3.0%
FY2022: 2.2%
Other revenue
4.9%

Who Are Their Customers?

Norgine holds commercial rights to the CHD combination in Europe, Australia and New Zealand; for approved products, Vir expects to use its own resources and third-party relationships to sell and distribute.

Do Revenues Turn Into Profits?

No. It lost $438M in FY2025.

Operating income, FY2025
−699% of revenue
▲ +18% (Loss) vs FY2024 (−$587.2M, −791%)
Net income, FY2025
−639% of revenue
▲ +16% (Loss) vs FY2024 (−$522M, −703%)
Free cash flow, FY2025
−579% of revenue
▲ +13% (Loss) vs FY2024 (−$453.7M, −611%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ Turned to a loss
vs $240K in Q3 FY2025
Net income
▲ +41% (Loss)
vs −$163.1M in Q3 FY2025
License and collaboration revenue share of revenue vs −27.1% in Q3 FY2025
  • Oct 9, 2026 Vir and Gilead agreed to develop three tumor-targeting candidates The collaboration covers discovery and engineering of dual-masked T-cell engager candidates for selected solid-tumor targets.
  • Oct 1, 2026 Vir appointed Aziz Sawaf as chief financial officer
  • Jul 20, 2026 The chief financial officer resigned Jason O’Byrne said he would step down to pursue another opportunity; Vir named an interim principal financial officer.

Shrinking. Revenue fell 94% in 4 years, from $1.1B in FY2021 to $68.6M in FY2025, about 50% a year.

Cancer added to the focus The older report centered on infectious-disease treatments and prevention; the latest describes work on serious infectious diseases and cancer, including solid-tumor candidates.

From marketed drug to clinical pipeline The older report described sotrovimab as a marketed product, while the latest business overview centers on investigational hepatitis delta and solid-tumor programs.

Revenue over time
License and collaboration revenue Grant revenue Other revenue Collaboration revenue Contract revenue License revenue from a related party
$2B$1B$0

Who Do They Compete With?

Competes with Gilead, Mirum, Bluejay Therapeutics, Huahui Health, Assembly Biosciences, Novartis, Janux, Johnson & Johnson, Regeneron, GSK, Bayer, Amgen, Merck, Pfizer, AstraZeneca, Roche, Daiichi Sankyo, Remegen, Jazz, and BioNTech

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support